you are right of course but if you had bought cphd anytime it was 3.3 or less for the entire year, you would have made money. they have a solid base and products that work, repeat buyers and a business plan that encourages renewables. with luck they will be profitable next year. they have a very small market cap 100 to 150 million, and if just the strep test is successful with 10% market penetration, which adds 500000 tests a year, they will be profitable. they only have to make 15 to 20 million a year to be profitable and that is about 500 cyclers and 1 million tubes and 500k to 1000K other tests. i think 700 cyclers is easily doable a million tubes is expected since they average over 1000 tubes per cycler now and with more sales they will do more.
with a profit of 5 million and a p to e of 30, that is a solid 5 for the stock without the expectation of more growth. if the air sampler takes hold they can sell it to hospitals.
medicis on the other hand is a risk averse company having been killed on the psoriasis vaccine. they have no killer apps and are dependent on the lack of development in dermatology for their survival
Market Data 
Markets 
AI
